These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 21853076)

  • 1. Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104.
    Benito J; Shi Y; Szymanska B; Carol H; Boehm I; Lu H; Konoplev S; Fang W; Zweidler-McKay PA; Campana D; Borthakur G; Bueso-Ramos C; Shpall E; Thomas DA; Jordan CT; Kantarjian H; Wilson WR; Lock R; Andreeff M; Konopleva M
    PLoS One; 2011; 6(8):e23108. PubMed ID: 21853076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models.
    Benito J; Ramirez MS; Millward NZ; Velez J; Harutyunyan KG; Lu H; Shi YX; Matre P; Jacamo R; Ma H; Konoplev S; McQueen T; Volgin A; Protopopova M; Mu H; Lee J; Bhattacharya PK; Marszalek JR; Davis RE; Bankson JA; Cortes JE; Hart CP; Andreeff M; Konopleva M
    Clin Cancer Res; 2016 Apr; 22(7):1687-98. PubMed ID: 26603259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.
    Konopleva M; Thall PF; Yi CA; Borthakur G; Coveler A; Bueso-Ramos C; Benito J; Konoplev S; Gu Y; Ravandi F; Jabbour E; Faderl S; Thomas D; Cortes J; Kadia T; Kornblau S; Daver N; Pemmaraju N; Nguyen HQ; Feliu J; Lu H; Wei C; Wilson WR; Melink TJ; Gutheil JC; Andreeff M; Estey EH; Kantarjian H
    Haematologica; 2015 Jul; 100(7):927-34. PubMed ID: 25682597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia models.
    Portwood S; Lal D; Hsu YC; Vargas R; Johnson MK; Wetzler M; Hart CP; Wang ES
    Clin Cancer Res; 2013 Dec; 19(23):6506-19. PubMed ID: 24088735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting.
    Chiarini F; Lonetti A; Evangelisti C; Buontempo F; Orsini E; Evangelisti C; Cappellini A; Neri LM; McCubrey JA; Martelli AM
    Biochim Biophys Acta; 2016 Mar; 1863(3):449-463. PubMed ID: 26334291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment.
    Frolova O; Samudio I; Benito JM; Jacamo R; Kornblau SM; Markovic A; Schober W; Lu H; Qiu YH; Buglio D; McQueen T; Pierce S; Shpall E; Konoplev S; Thomas D; Kantarjian H; Lock R; Andreeff M; Konopleva M
    Cancer Biol Ther; 2012 Aug; 13(10):858-70. PubMed ID: 22785211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity.
    Singleton RS; Guise CP; Ferry DM; Pullen SM; Dorie MJ; Brown JM; Patterson AV; Wilson WR
    Cancer Res; 2009 May; 69(9):3884-91. PubMed ID: 19366798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.
    Abbattista MR; Jamieson SM; Gu Y; Nickel JE; Pullen SM; Patterson AV; Wilson WR; Guise CP
    Cancer Biol Ther; 2015; 16(4):610-22. PubMed ID: 25869917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors.
    Lindsay D; Garvey CM; Mumenthaler SM; Foo J
    PLoS Comput Biol; 2016 Aug; 12(8):e1005077. PubMed ID: 27560187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302.
    Lohse I; Rasowski J; Cao P; Pintilie M; Do T; Tsao MS; Hill RP; Hedley DW
    Oncotarget; 2016 Jun; 7(23):33571-80. PubMed ID: 27248663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104.
    Patterson AV; Ferry DM; Edmunds SJ; Gu Y; Singleton RS; Patel K; Pullen SM; Hicks KO; Syddall SP; Atwell GJ; Yang S; Denny WA; Wilson WR
    Clin Cancer Res; 2007 Jul; 13(13):3922-32. PubMed ID: 17606726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oroxylin A reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12/CXCR7 axis in bone marrow microenvironment.
    Li W; Ding Q; Ding Y; Lu L; Wang X; Zhang Y; Zhang X; Guo Q; Zhao L
    Mol Carcinog; 2017 Mar; 56(3):863-876. PubMed ID: 27533597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of bone marrow adipocytes in leukemia and chemotherapy challenges.
    Samimi A; Ghanavat M; Shahrabi S; Azizidoost S; Saki N
    Cell Mol Life Sci; 2019 Jul; 76(13):2489-2497. PubMed ID: 30715556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer.
    Sun JD; Liu Q; Wang J; Ahluwalia D; Ferraro D; Wang Y; Duan JX; Ammons WS; Curd JG; Matteucci MD; Hart CP
    Clin Cancer Res; 2012 Feb; 18(3):758-70. PubMed ID: 22184053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of CD82 by a monoclonal antibody potentiates anti-leukemia effects of AraC in vivo.
    Nishioka C; Ikezoe T; Yokoyama A
    Cancer Med; 2015 Sep; 4(9):1426-31. PubMed ID: 26139471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia promotes chemoresistance in acute lymphoblastic leukemia cell lines by modulating death signaling pathways.
    Petit C; Gouel F; Dubus I; Heuclin C; Roget K; Vannier JP
    BMC Cancer; 2016 Sep; 16(1):746. PubMed ID: 27658583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paradoxical effects of Auger electron-emitting (111)In-DTPA-NLS-CSL360 radioimmunoconjugates on hCD45(+) cells in the bone marrow and spleen of leukemia-engrafted NOD/SCID or NRG mice.
    Bergstrom D; Leyton JV; Zereshkian A; Chan C; Cai Z; Reilly RM
    Nucl Med Biol; 2016 Oct; 43(10):635-41. PubMed ID: 27497632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia.
    Guise CP; Wang AT; Theil A; Bridewell DJ; Wilson WR; Patterson AV
    Biochem Pharmacol; 2007 Sep; 74(6):810-20. PubMed ID: 17645874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice.
    Gu Y; Guise CP; Patel K; Abbattista MR; Li J; Sun X; Atwell GJ; Boyd M; Patterson AV; Wilson WR
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):543-55. PubMed ID: 20473609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.
    Wilson WR; Hicks KO; Pullen SM; Ferry DM; Helsby NA; Patterson AV
    Radiat Res; 2007 Jun; 167(6):625-36. PubMed ID: 17523848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.